Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection

Current Opinion in Infectious Diseases

Volumn 27, Issue 1, 2014, Pages 36-45

  Karageorgopoulos, Drosos E ^a   El Sherif, Omar ^b   Bhagani, Sanjay ^a,c   Khoo, Saye H ^d  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antiviral agents; drug interactions; hepatitis C; HIV infection; pharmacokinetics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BOCEPREVIR; DACLATASVIR; EFAVIRENZ; FALDAPREVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OXIDOREDUCTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; PROTEASE INHIBITORS;

EID: 84891825080     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000034     Document Type: Review

References (53)

1. Wilby KJ, Partovi N, Ford JA, et al. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012; 26:205-210.
2. Gonzalez-Moreno J, Payeras-Cifre A. Hepatitis C virus infection: looking for interferon free regimens. Sci World J 2013; 2013:825375.
3. Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment: finding the right path. Nat Rev Drug Discov 2007; 12:991-1000. (Pubitemid 350201789)
4. Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2012; 158:114-123.
5. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35:647-662.
6. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44.
7. Manns MP, von Hahn T. Novel therapies for hepatitis C: one pill fits all? Nat Rev Drug Discov 2013; 12:595-610.
8. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-1617.
9. Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections. J HIV Ther 2003; 8:77-84.
10. Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197:1558-1566. (Pubitemid 351706486)
11. Sherman KE, Thomas D, Chung RT. Human immunodeficiency virus and liver disease forum 2012. Hepatology 2013. [Epub ahead of print]
12. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
13. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
14. Klein MB, Rollet KC, Hull M, et al. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. Antivir Ther 2013; 18:717-721.
15. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65:1079-1085.
16. Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract]. In: 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA. Abstr. no. 118.
17. Rhee EG, Feng H-p, Xuan F, et al. Absence of a significant pharmacokinetic interaction between the HCV protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine [abstract]. In: 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA. Abstr. no. 537.
18. Hammond KP, Wolfe P, Burton JR Jr, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013; 62:67-73.
19. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013; 56:718-726.
20. de Kanter CT, Blonk MI, Colbers AP, et al. Lack of a clinically significant drugdrug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013; 56:300-306.
21. Johnson M, Borland J, Chen S, et al. The effect of boceprevir and telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects [abstract]. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy; 22-24 April 2013; Amsterdam. Abstr. no. O-16.
22. Vourvahis M, Plotka A, Kantaridis C, et al. The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers [abstract]. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy; 22-24 April 2013; Amsterdam. Abstr. O-17.
23. Van Heeswijk R, Gysen V, Boogaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting of the Infectious Diseases Society of America (IDSA), 25-28 October 2008; Washington, DC. Abstr. A-966.
24. Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract]. In: 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011, Boston, MA. Abstr. no. 119.
25. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013; 75:431-439.
26. Kakuda T, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, twoway crossover trial [abstract]. In: 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona. Abstr. no. O-18.
27. Van Heeswijk R, Garg V, Boogaerts G, et al. Interaction between telaprevir and raltegravir in healthy volunteers [abstract]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago, IL. Abstr. A1-1738a.
28. Sabo JP, Kort J, Haschke M, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers [abstract]. In: 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA. Abstr. no. 25.
29. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [abstract]. In: IDWeek 2012; 17-21 October 2012; San Diego, CA. Abstr. no. 36620.
30. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013. 10.3851/IMP2674. [Epub ahead of print]
31. Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers [abstract]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 9-12 November 2012; Boston, MA. Abstr. no. 1877.
32. Garnock-Jones KP. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection. Drugs 2012; 72:2431-2456.
33. Garraffo R, Poizot-Martin I, Piroth L, et al. Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) [abstract]. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy; 22-24 April 2013; Amsterdam. Abstr. no. O-15.
34. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
35. Garg V, Kauffman RS, Beaumont M, et al. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther 2012; 17:1211-1221.
36. Kiang TK, Wilby KJ, Ensom MH. Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet 2013; 52:487-510.
37. Buti M, Agarwal K, Horsmans Y, et al. OPTIMIZE Trial: noninferiority of twicedaily telaprevir versus administration of every 8 h in treatment-na? ̈ve, genotype 1 HCV infected patients [abstract]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, 9-13 November, 2012, Boston, MA; 2012. pp. 9-12.
38. Garg V, Luo X, McNair L, et al. The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract]. In: 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA. Abstr. no. 629.
39. Thomas DL, Bartlett JG, Peters MG, et al. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012; 54:979-983.
40. Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10:596-606.
41. Mathias A, Clinical pharmacology of DAA's for HCV: what's new and what's in the pipeline [abstract]. In: 14th International Workshop on Clinical Pharmacology of HIV, Therapy Session, April 22-24, 2013, Amsterdam, Netherlands.
42. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis-a practical guide. Aliment Pharmacol Ther 2013; 37:1132-1156.
43. Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother 2013; 68:1354-1359.
44. Schwarze-Zander C, Rockstroh JK. HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? AIDS 2012; 26:1845-1846.
45. Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009; 64:5-8.
46. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-120.
47. Herold C, Heinz R, Niedobitek G, et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21:260-265. (Pubitemid 32677382)
48. Micheli V, Regazzi M, Dickinson L, et al. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit 2008; 30:306-313.
49. Chalasani N, Gorski JC, Patel NH, et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001; 34:1103-1108. (Pubitemid 33096581)
50. Neumann A, Polis M, Rozenberg L, et al. Differential antiviral effect of PEGinterferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 2007; 21:1855-1865. (Pubitemid 47329762)
51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
52. Solas C, Pambrun E, Winnock M, et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012; 26:2193-2199.
53. Krakower D, Kwan CK, Yassa DS, et al. iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis 2010; 51:813-822.